Keith Stuart
Expertise in
28
conditions

Dr. Keith Stuart

Oncology
Office
41 Mall Rd, 
Burlington, MA 
Expertise in
28
conditions
Office
41 Mall Rd, 
Burlington, MA 

Overview

Keith Stuart is an Oncologist practicing medicine in Burlington, Massachusetts.

Dr. Stuart is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Fibrolamellar Carcinoma, Colorectal Cancer, Familial Colorectal Cancer, Familial Pancreatic Cancer, and Liver Embolization.

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 5 clinical trials.

Specialties

Oncology

Licenses

Specialist in MA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Office
41 Mall Rd, Burlington, MA 01805
Other Locations
Lahey Medical Center Peabody
1 Essex Center Dr, Peabody, MA 01960

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
View 4 Less Clinical Trials

5 Total Publications

Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma.
Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma.
Journal: Journal of gastrointestinal oncology
Published: January 05, 2018
Similar Doctors
Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

Office

52 Second Ave Ste 1110, 
Waltham, MA 
 (8.7 miles away)
781-487-6100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edwin Choy is an Oncologist practicing medicine in Waltham, Massachusetts. Dr. Choy is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Chordoma, and Osteosarcoma.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Abramson is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Abramson is highly rated in 27 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Davids is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Davids is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Keith Stuart

How do I make an appointment with Dr. Keith Stuart?

You can book an appointment with Dr. Keith Stuart by calling their office at 781-744-8000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Keith Stuart a top-rated expert for Fibrolamellar Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Keith Stuart is classified as an Distinguished expert for Fibrolamellar Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Keith Stuart specialize in?

While Dr. Keith Stuart is a Oncology, they have specific expertise in Fibrolamellar Carcinoma, Colorectal Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Keith Stuart participate in research or clinical trials?

Yes. Dr. Keith Stuart has published 5 articles and abstracts on conditions like Fibrolamellar Carcinoma. You can view a list of Dr. Keith Stuart's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Keith Stuart accept my insurance?

Dr. Keith Stuart accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 781-744-8000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stuart's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 19 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile